VOCAL BIOMARKERS MARKET ANALYSIS

Vocal Biomarkers Market – Insights

Sound vibrations are used in therapeutic healing for mental health conditions such as depression and anxiety. Recent research has broadened its application for diagnosis of cardiovascular and other diseases.  Biomarkers in the voice of a person have been linked to disorders such as depression, coronary artery disease, and anxiety. Moreover, HIPAA compliant vocal biomarker systems are expected to serve as an effective alternative to current diagnostic techniques such as MRI, X-Ray, and CT scan, owing to successful completion of clinical trials. Research is also underway for identifying vocal biomarkers in the diagnosis of Parkinson’s disease, traumatic brain injury, cognitive impairment, and respiratory disorders, which is expected to offer growth opportunities for market players. Companies operating in the field of voice technology are sampling voice data to provide accurate results. For instance, Beyond Verbal, Inc. has been researching on vocal biomarkers since 1996, and has collected over 2.5 million voice samples in over 40 different languages.

The global vocal biomarkers market size is expected to be valued at US$ 1,357.7 million in 2019, and is expected to exhibit a CAGR of 15.5% over the forecast period (2019 – 2027).

Figure 1. Global Vocal Biomarkers Market Value (US$ Mn), by Region, 2019

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of psychological and cardiovascular disease is expected to propel growth of the vocal biomarkers market

Increasing prevalence of psychological and cardiovascular diseases is expected to drive growth of the vocal biomarkers market over the forecast period. For instance, according to the American Stroke Association 2015, cardiovascular disorders was the main cause of death worldwide, accounting for 17.3 Mn deaths per year, which is expected to reach 23.6 Mn by 2030. Moreover, according to the Alzheimer’s Association, in 2017, about 5.5 million people in the U.S suffered from Alzheimer's and dementia, which demands rapid research on biomarkers for early detection of Alzheimer Disease.

Furthermore, vocal biomarker technology systems would act as an ideal cost-effective primary diagnostic tools that could help discern if the patient needs to further opt for expensive X-Ray/MRI/CT/EEG/ECG scans. Thus, many people suffering from these chronic ailments explicates large potential for vocal biomarkers technology in the commercial space in the long run.

Moreover, conventional diagnostic systems need to adhere to stringent regulations concerning to radiation, whereas, the voice-based systems are based on technology that does not use any form of radiation and thus, is expected to gain significant traction over the forecast period.

Figure 2. Global Vocal Biomarkers Market Share (%), by Therapeutic Applications, 2019 and 2027

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2019)

Rising demand for minimally invasive techniques is expected to drive growth of the vocal biomarkers market

MRI, CT, X-ray, and ECG, are minimally invasive technologies and are out of reach in the emerging economies. Moreover, minimally invasive procedures are preferred by patients due to advantages such as speedy recovery. However, high costs of these techniques results in substantial healthcare burden on the economy.

Key Players

Major players operating in the global vocal biomarkers market include Beyond Verbal, Inc., Sonde Health Inc., Sharecare, Inc., IBM Coporation, and Cogito Corporation